Navigation Links
Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc.
Date:7/23/2014

ROCHESTER, N.Y., July 23, 2014 /PRNewswire/ -- The Board of Directors of VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, announced today that Eric T. Converse, 48, has been named president and chief executive officer, effective immediately.  Mr. Converse joined the company's Board of Directors in August 2013 and has held the positions of interim president and chief executive officer since October 25, 2013.

Dr. Charles E. Phelps, Ph.D., chairman of the company's Board of Directors, said, "During the past nine months, Eric has clearly demonstrated his leadership and team-building skills on a number of fronts and has earned the respect and cooperation from VirtualScopics' senior management team, employees, industry thought leaders and customers.  His contributions to the company thus far include: negotiating a global operational and commercialization alliance with IXICO plc, the brain health company, based in the United Kingdom; working closely with VirtualScopics and IXICO senior management to form a joint Scientific Advisory Board to benefit both companies; and the recent opening of a joint office in New Hope, Pennsylvania.  The new office is located in the heart of the big pharma corridor, providing project management teams from both companies the opportunity to work more closely with existing and prospective customers to determine their clinical trial imaging needs."  Dr. Phelps added, "With the assistance of Korn Ferry, International, the Board of Directors conducted an extensive search that brought forward numerous candidates with strong skills and backgrounds, a number of whom eagerly sought the CEO position at VirtualScopics.  In the Board's judgment, the leadership demonstrated by Eric during his term as interim CEO made it clear that he was the best choice to take the Company forward."  

Mr. Converse added, "I am very pleased to be working with this team.  Our focus on our employees and infrastructure investments has shown early results with increases in customer wins that will ultimately lead to improved shareholder value.  As I strongly believe a good team will yield good results, I am extremely excited to continue with this great team and deliver even greater results." Converse continued, "The first six months of 2014 represents the company's best start in terms of bookings and awards outstanding in the history of the company, a testament to the strong commitment and dedication of the entire VirtualScopics team.  We are all excited about our recent alliance with IXICO and the many benefits of this relationship that are already coming to fruition."

Mr. Converse has more than 20 years of hands-on management experience working with early-stage companies across a wide range of industries.  He received his bachelor's degree from Michigan State University and attended Erasmus University in Rotterdam, The Netherlands.

About VirtualScopics, Inc.
VirtualScopics, Inc. (NASDAQ: VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services.  For more information on VirtualScopics, Inc., please visit www.virtualscopics.com.

Forward-looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure, the strategic alliance with IXICO and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions.  Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.  These include without limitation:  the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed.  Other risks include the Company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others.  All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner
Donna Stein & Partners
315-361-4672
Email:  dstein1@twcny.rr.com


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Board of Directors Appoints Eric Converse Interim Chief Executive Officer, Announces Resignation of Jeff Markin
2. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
3. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
4. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
5. Dr. Phillip Chan Named Finalist for Ernst & Young Entrepreneur of the Year® 2012 Award in New Jersey
6. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
7. StreamVenue Healthcare CEO Named Peoples Choice Winner
8. Masimo CEO Joe Kiani Named Ernst & Young Entrepreneur of the Year
9. Prime Therapeutics Named a Top Workplace by the Minneapolis Star Tribune
10. WellTok Named Colorado Company to Watch for 2012
11. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Research and Markets has ... (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, ... offering. ... Global Hearing Aids Market Sales Volume, Company Analysis and Forecast ... hearing aid industry. The growing prevalence of hearing ...
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, a ... announced the launch of an opioid management program ... on opioids and helps stem the growing tide ... prescribed to treat chronic non-cancer pain (back pain, ... risks and lack of evidence regarding long-term effectiveness. ...
(Date:1/19/2017)... -- Germany Cataract Surgery Devices Market ... "Germany Cataract Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company ... bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, SC. ... scientist who was determined to create a line of products that would elevate her ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... "TransFlare 4K ... use inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... ... ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to support ... author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, his ... of age, he joined the Navy and got married right out of boot camp. ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton ... (OPEP) device, was featured in a study indicating superior performance against competitive products ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published ...
Breaking Medicine News(10 mins):